Friday, 18 October 2019

WuXi's API manufacturing passes FDA inspection

19 August 2014 | Regulatory | By BioSpectrum Bureau

WuXiPharmaTech passed inspection for API manufacturing base

WuXiPharmaTech passed inspection for API manufacturing base

Singapore: China-based WuXiPharmaTech, pharmaceutical, biotechnology and medical device research and development outsourcing company, has succesfully passed the US Food and Drug Administration (FDA) inspection for its Shanghai SynTheAll Pharmaceutical subisidiary for the manufacturing unit of active pharmaceutical ingredient (API) for a branded commercial drug.

"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr Ge Li, chairman and CEO of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls